BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14981934)

  • 1. Intraperitoneal administration of pMP6/liposome complexes inhibits the growth of co-localized colon-26 adenocarcinoma cells by inducing a tumor-specific immune response.
    Sturlan S; Schneeberger A; Fang M; Beinhauer BG; Lührs P; Kutil R; Wessner B; Huang L; Aasen AO; Rogy MA
    Anticancer Res; 2003; 23(6C):4843-51. PubMed ID: 14981934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
    Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
    Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM
    Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
    Chang CY; Lee J; Kim EY; Park HJ; Kwon CH; Joh JW; Kim SJ
    BMC Cancer; 2007 May; 7():87. PubMed ID: 17519043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Flt3 ligand from Pichia pastoris inhibits growth of lymphoma and colon adenocarcinoma in mice.
    Zhang YL; Wei YJ; Deng YC; Wang YD; Liu CZ; Su L; Yang KG; Chen SS
    J Exp Ther Oncol; 2006; 5(3):161-6. PubMed ID: 16528967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice.
    Charoensit P; Kawakami S; Higuchi Y; Yamashita F; Hashida M
    Cancer Gene Ther; 2010 Jul; 17(7):512-22. PubMed ID: 20414324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amount of interleukin 12 available at the tumor site is critical for tumor regression.
    Colombo MP; Vagliani M; Spreafico F; Parenza M; Chiodoni C; Melani C; Stoppacciaro A
    Cancer Res; 1996 Jun; 56(11):2531-4. PubMed ID: 8653692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
    Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
    J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo gene transfer of murine interleukin-4 inhibits colon-26-mediated cancer cachexia in mice.
    Sturlan S; Beinhauer BG; Oberhuber G; Huang L; Aasen AO; Rogy MA
    Anticancer Res; 2002; 22(5):2547-54. PubMed ID: 12529962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
    Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
    J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of innate immunological factors by STEALTH liposome-encapsulated tumor necrosis factor-alpha in a colon tumor xenograft model.
    Kim DW; Andres ML; Kajioka EH; Dutta-Roy R; Miller GM; Seynhaeve AL; ten Hagen TL; Gridley DS
    Anticancer Res; 2002; 22(2A):777-88. PubMed ID: 12014650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
    Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
    Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice.
    Mizuno Y; Naoi T; Nishikawa M; Rattanakiat S; Hamaguchi N; Hashida M; Takakura Y
    J Control Release; 2010 Jan; 141(2):252-9. PubMed ID: 19778560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1beta mediated by a tumor-specific vector, HVJ cationic liposomes.
    Miyata T; Yamamoto S; Sakamoto K; Morishita R; Kaneda Y
    Cancer Gene Ther; 2001 Nov; 8(11):852-60. PubMed ID: 11773975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting KITENIN, a metastasis-enhancing protein.
    Lee JH; Cho ES; Kim MY; Seo YW; Kho DH; Chung IJ; Kook H; Kim NS; Ahn KY; Kim KK
    Cancer Res; 2005 Oct; 65(19):8993-9003. PubMed ID: 16204073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
    Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
    Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.